Latest market price
3.79
-0.26-6.42%
OverviewShort InterestFilings
VNDAQT35Vanda Pharmaceuticals Inc.·NASDAQ
3.79-6.42%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-4.62Insider Own10.66%Shs Outstand60.46MPerf Week-5.49%
Market Cap229.15MForward P/E—EPS next Y-0.72Insider Trans0.00%Shs Float57.20MPerf Month-21.21%
Enterprise Value111.15MPEG—EPS next Q—Short Float14.53%Perf Quarter-27.53%
Income-276.00MP/S1.00EPS this Y—Short Ratio8.59Perf Half Y-45.86%
Sales230.00MP/B1.15EPS next Y—ROA-71.88%Short Interest8.31MPerf YTD-57.03%
Book/sh3.31P/C1.64EPS next 5Y—ROE-106.94%52W High9.94 -61.87%Perf Year-29.94%
Cash/sh2.32P/FCF—EPS past 3/5Y—ROIC-76.68%52W Low3.74 1.34%Perf 3Y-11.45%
Dividend Est.—EV/EBITDA—Sales past 3/5Y-5.26% -2.73%Gross Margin92.72%Volatility8.80% 5.43%Perf 5Y-79.29%
Dividend TTM—EV/Sales0.48EPS Y/Y TTM—Oper. Margin-77.59%ATR (14)0.25Perf 10Y-76.22%
Dividend Ex-Date—Quick Ratio1.53Sales Y/Y TTM8.49%Profit Margin-119.87%RSI (14)26.67Recom2.37
Dividend Gr. 3/5Y—Current Ratio1.54EPS Q/Q2.63%SMA20-9.97%Beta0.71Target Price15.50
Payout0.00%Debt/Eq0.11Sales Q/Q25.00%SMA50-20.88%Rel Volume1.70Prev Close4.05
Employees533LT Debt/Eq0.09EarningsFeb 10SMA200-39.01%Avg Volume1.06MPrice3.79
IPO DateApr 12, 2006Option/ShortYes / YesEPS/Sales Surpr.45.75% 0.89%Net Debt/EBITDA—Volume1,791,645Change-6.42%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-23-26InitiatedOppenheimerOutperform$10
May-11-26ReiteratedHC Wainwright & Co.Buy
Feb-23-26ReiteratedHC Wainwright & Co.Buy
Jan-05-26ReiteratedHC Wainwright & Co.Buy
Dec-31-25ReiteratedJefferiesHold$7.50
Nov-05-25ReiteratedB.Riley Financial$11
Jul-11-24InitiatedCantor FitzgeraldOverweight$11
Feb-25-22DowngradeJefferiesBuy → Hold
Jan-14-21DowngradeCitigroupBuy → Neutral
Oct-29-20UpgradeCitigroupNeutral → Buy
Latest News· Times ET
Oct-29-26
Oct-29-2604:05AM
12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga
02:58AM
Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcriptseekingalpha.com
Oct-28-26
Oct-28-2608:05PM
Vanda Pharmaceuticals Q3 Earnings Call Highlightsmarketbeat.com
06:20PM
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimateszacks.com
04:01PM
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Resultsprnewswire.com
Oct-27-26
Oct-27-2602:13PM
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomesbenzinga.com
06:50AM
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomitingprnewswire.com
Oct-22-26
Oct-22-2609:00AM
Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?Yahoo
Oct-21-26
Oct-21-2605:40PM
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026prnewswire.com
Oct-15-26
Oct-15-2611:45AM
Vanda Pharmaceuticals: Cash Is Running Out Faster Than The LaunchesSeekingAlpha
08:47AM
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpointbenzinga.com
Oct-14-26
Oct-14-2605:40PM
Vanda says anxiety drug failed main goal of late-stage study, puts program on holdreuters.com
05:00PM
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Programprnewswire.com
Oct-05-26
Oct-05-2608:07AM
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as “Buy” by HC Wainwrightdefenseworld.net
03:28AM
HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price TargetBenzinga
Company

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue230216199193—————
Cost of Goods Sold Incl. D&A17131115—————
Gross Profit213203187178—————
Selling, General and Administrative Excl. Other263238146113—————
Research and Development1221097477—————
Other Operating Expense6782—————
Operating Income-178-151-41-14—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)6131820—————
Net Income Before Taxes-170-139-236—————
Income Taxes10382-44—————
Consolidated Net Income-276-220-193—————
Net Income From Continuing Operations-276-220-193—————
Net Income-276-220-193—————
EPS (Recurring)-4.62-3.74-0.320.04—————
EPS (Basic, Before Extraordinaries)-4.62-3.74-0.320.04—————
EPS (Diluted)-4.62-3.74-0.320.04—————
EBITDA-163-127-159—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio———96.79—————
Price To Sales Ratio0.992.411.401.25—————
Gross Margin92.6193.9893.9792.23—————
Operating Margin-77.39-69.91-20.60-7.25—————
Net Margin-120.00-101.85-9.551.55—————
Shares Outstanding60595857—————
Market Capitalization227520278241—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$10.43$8.55$6.68$4.80$2.92● Close Price0.00M0.65M1.29M1.94M2.58MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Williams TimothySVP & General CounselMar 02 '26Sale8.2742,434350,755377,450Mar 04
Moran Kevin PatrickSVP, CFO & TreasurerMar 02 '26Sale8.2742,442350,821411,380Mar 04
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 02 '26Sale8.2730,800254,590333,469Mar 04
Polymeropoulos Mihael HristosPresident and CEOMar 02 '26Sale8.17156,2351,276,9712,704,496Mar 04
Birznieks GuntherSVP, Business DevelopmentMar 02 '26Sale8.2742,431350,730494,197Mar 04
Honore TageDirectorFeb 23 '26Sale8.0330,000240,90093,469Feb 24
Polymeropoulos Mihael HristosPresident and CEOAug 07 '25Buy4.1510,00041,5002,335,731Aug 08
Mitchell Stephen RayDirectorJun 13 '25Sale4.597,00032,13097,082Jun 16
Polymeropoulos Mihael HristosPresident and CEOMay 21 '25Buy4.4010,00043,9962,325,731May 21
Polymeropoulos Mihael HristosPresident and CEOMay 16 '25Buy4.2220,00084,4722,315,731May 19
Polymeropoulos Mihael HristosPresident and CEOMar 06 '25Buy5.0110,00050,1502,295,731Mar 06
Polymeropoulos Mihael HristosPresident and CEOMar 05 '25Buy5.0210,00050,2002,285,731Mar 05
Polymeropoulos Mihael HristosPresident and CEOMar 03 '25Buy4.7110,00047,0502,275,731Mar 04
Polymeropoulos Mihael HristosPresident and CEOFeb 28 '25Buy4.7610,00047,6002,361,730Feb 28
Polymeropoulos Mihael HristosPresident and CEOFeb 27 '25Buy4.7610,00047,6002,351,730Feb 27
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.